Advertisement
U.S. markets open in 3 hours 17 minutes
  • S&P Futures

    5,304.25
    -4.00 (-0.08%)
     
  • Dow Futures

    40,140.00
    -4.00 (-0.01%)
     
  • Nasdaq Futures

    18,483.00
    -20.75 (-0.11%)
     
  • Russell 2000 Futures

    2,135.60
    -2.80 (-0.13%)
     
  • Crude Oil

    81.94
    +0.59 (+0.73%)
     
  • Gold

    2,218.50
    +5.80 (+0.26%)
     
  • Silver

    24.57
    -0.18 (-0.74%)
     
  • EUR/USD

    1.0783
    -0.0047 (-0.43%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.00
    +0.22 (+1.72%)
     
  • GBP/USD

    1.2605
    -0.0033 (-0.26%)
     
  • USD/JPY

    151.4420
    +0.1960 (+0.13%)
     
  • Bitcoin USD

    70,626.32
    +606.93 (+0.87%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,972.65
    +40.67 (+0.51%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

AstraZeneca's Farxiga fails to get FDA approval for Type-1 diabetes

July 15 (Reuters) - British drugmaker AstraZeneca Plc said on Monday the U.S. Food and Drug Administration declined to approve its diabetes treatment, Farxiga, for use as a supplement to insulin in adults with Type-1 diabetes.

The company said the regulator had issued a complete response letter, declining its application for using Farxiga in the new indication.

Farxiga is already approved in the United States for use in Type-2 diabetes. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

Advertisement